Literature DB >> 9139240

Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood.

V Hinz1, S Grewig, B H Schmidt.   

Abstract

Cholinesterase activities in rat forebrain, erythrocytes, and plasma were assessed after a single oral administration of metrifonate or dichlorvos. In 3-month-old rats, the dichlorvos (10 mg/kg p.o.)induced inhibition of cholinesterase reached its peak in brain after l5-45 min and after 10-30 min in erythrocytes and plasma. Cholinesterase activity recovered rapidly after the peak of inhibition, but did not reach control values in brain and erythrocytes within 24 h after drug administration. The recovery of plasma cholinesterase activity, in contrast, was already complete 12 h after dichlorvos treatment. Metrifonate (100 mg/kg p.o.) had qualitatively similar inhibition kinetics as dichlorvos, albeit with a slightly delayed onset. Peak values were attained 45-60 min (brain) and 20-45 min (blood), after drug administration. Apparently complete recovery of cholinesterase activity was noted in both tissues 24 h after treatment. The dose-dependence of drug-induced inhibition of cholinesterase in rat blood and brain was determined at the time of maximal inhibition, i.e., 30 min after dichlorvos treatment and 45 min after metrifonate treatment. The oral ED(50) values obtained for dichlorvos were 8 mg/kg for brain and 6 mg/kg for both erythrocyte and plasma cholinesterase. The corresponding oral ED(50) values for metrifonate were 10 to 15 times higher, i.e., 90 mg/kg in brain and 80 mg/kg in erythrocytes and plasma. In rats deprived of food for 18 h before drug treatment, the corresponding ED(50) values for metrifonate were 60 and 45 mg/kg, respectively, indicating an about two-fold higher sensitivity of fasted rats to metrifonate-induced cholinesterase inhibition compared to non-fasted rats. Compared to 3-month-old rats, 19-month-old rats showed a higher sensitivity towards metrifonate and dichlorvos. At the time of maximal inhibition, there was a strong correlation between the degree of cholinesterase inhibition in brain and blood. These results demonstrate that single oral administration of metrifonate and dichlorvos induces an inhibition of blood and brain cholinesterase in the conscious rat in a dose-dependent and apparently fully reversible manner. While the efficiency of a given dose of inhibitor may vary with the satiety status or age of the animal, the extent of brain ChE inhibition can be estimated from the level of blood ChE activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9139240     DOI: 10.1007/bf02531650

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  29 in total

1.  Studies on the toxicity and mechanism of action of dipterex.

Authors:  K P DUBOIS; G J COTTER
Journal:  AMA Arch Ind Health       Date:  1955-01

2.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

3.  Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation.

Authors:  D C Mash; D D Flynn; L T Potter
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

4.  Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease.

Authors:  J A Richter; E K Perry; B E Tomlinson
Journal:  Life Sci       Date:  1980-05-19       Impact factor: 5.037

5.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

Authors:  P J Whitehouse; D L Price; R G Struble; A W Clark; J T Coyle; M R Delon
Journal:  Science       Date:  1982-03-05       Impact factor: 47.728

6.  Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain.

Authors:  M Hallak; E Giacobini
Journal:  Neuropharmacology       Date:  1989-03       Impact factor: 5.250

7.  Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits.

Authors:  L M Bierer; V Haroutunian; S Gabriel; P J Knott; L S Carlin; D P Purohit; D P Perl; J Schmeidler; P Kanof; K L Davis
Journal:  J Neurochem       Date:  1995-02       Impact factor: 5.372

8.  Transformation and action of metrifonate.

Authors:  I Nordgren; M Bergström; B Holmstedt; M Sandoz
Journal:  Arch Toxicol       Date:  1978-10-13       Impact factor: 5.153

Review 9.  Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease.

Authors:  V Kumar; R E Becker
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-10

10.  Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.

Authors:  S A Beller; J E Overall; A C Swann
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  4 in total

1.  Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation.

Authors:  Jos Prickaerts; Ayhan Sik; Franz Josef van der Staay; Jan de Vente; Arjan Blokland
Journal:  Psychopharmacology (Berl)       Date:  2004-07-24       Impact factor: 4.530

2.  Kinetics of brain cholinesterase inhibition following metrifonate administration.

Authors:  S Dachir; B H Schmidt; A Levy
Journal:  Neurochem Res       Date:  1999-08       Impact factor: 3.996

3.  Effects of subchronic administration of metrifonate on cholinergic neurotransmission in rats.

Authors:  V C Hinz; J Kolb; B H Schmidt
Journal:  Neurochem Res       Date:  1998-07       Impact factor: 3.996

4.  Polypyridylruthenium(II) complexes exert anti-schistosome activity and inhibit parasite acetylcholinesterases.

Authors:  Madhu K Sundaraneedi; Bemnet A Tedla; Ramon M Eichenberger; Luke Becker; Darren Pickering; Michael J Smout; Siji Rajan; Phurpa Wangchuk; F Richard Keene; Alex Loukas; J Grant Collins; Mark S Pearson
Journal:  PLoS Negl Trop Dis       Date:  2017-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.